Is Ibogaine Legal in the US?

Is ibogaine legal in the US? In the sources we read on 30 October 2026, ibogaine is listed as a Schedule I controlled substance in federal regulation. In the Controlled Substances Act, Schedule I is the category for a substance with a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. In practice, the Act makes it unlawful to knowingly or intentionally manufacture, distribute or dispense a controlled substance, or to possess one, except as the Act authorizes, and the authorizations it names include a DEA registration. No source we read says the Schedule I listing has been removed. Recent federal and state actions concern research and future access, not a change in that listing. This page explains what the official texts say, what changed in 2025 and 2026, and what the sources do not tell us about Mexico. It is general information, not legal advice, and it does not say whether any person, clinic or program is acting lawfully.

What federal regulation says

The Drug Enforcement Administration's list of Schedule I hallucinogenic substances includes ibogaine as entry (d)(21) of 21 CFR 1308.11, with the alternate name Tabernanthe iboga and DEA code 7260. The paragraph covers any material, compound, mixture or preparation that contains any quantity of the listed substances, unless it is specifically excepted or listed in another schedule.

The statute that sets the Schedule I criteria is 21 U.S.C. 812. It says a Schedule I drug has a high potential for abuse, has no currently accepted medical use in treatment in the United States, and lacks accepted safety for use under medical supervision. Those are the statutory criteria for the category, not a finding by this page about ibogaine's value or risk.

What the listing means in practice. The Controlled Substances Act says that, except as the Act authorizes, it is unlawful for any person knowingly or intentionally to manufacture, distribute or dispense a controlled substance, or to possess one with intent to do so (21 U.S.C. 841). A separate provision makes it unlawful knowingly or intentionally to possess a controlled substance unless it was obtained directly, or under a valid prescription or order, from a practitioner acting in the course of professional practice, or as otherwise authorized by the Act (21 U.S.C. 844). People who manufacture, distribute or dispense controlled substances must hold a registration from the Attorney General (21 U.S.C. 822), and applications to do research with Schedule I substances are referred for review of the practitioner's qualifications and the merits of the research protocol (21 U.S.C. 823). We quote these provisions to show how the category works. We do not apply them to any person or clinic, and we do not describe penalties or case law.

What changed in 2025 and 2026

Two developments are easy to mistake for legalization. Neither is, on the text we read.

A federal executive order. On 18 April 2026 the President signed Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness. Section 1 says that psychedelic drugs, including ibogaine compounds, show potential in clinical studies for serious mental illness, and states a policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs. Section 2 directs the Food and Drug Administration and the DEA to facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act, including any necessary Schedule I handling authorizations for treating physicians and researchers, consistent with 21 U.S.C. 823. Section 5 is narrower than it is often described. It directs the Attorney General, in consultation with HHS, to review any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act. That is a review of specific products after Phase 3 trials, with rescheduling only if appropriate and only for products later approved by FDA. It is not a reclassification of ibogaine. Section 6 says the order is to be implemented consistent with applicable law and subject to the availability of appropriations, and that it creates no enforceable right. We found no regulation in this research that moved ibogaine out of Schedule I.

An FDA request for information. On 5 October 2026 the FDA announced a request for information on the design of early-phase clinical trials for ibogaine drug products (docket FDA-2026-N-10429, comments due 20 November 2026). The announcement concerns trial design and safety monitoring. It does not address scheduling or legalization, and we did not read the Federal Register notice itself.

Texas funding for clinical trials. Texas passed Senate Bill 2308 in 2025, adding Chapter 491, "Ibogaine Treatment," to the state Health and Safety Code. Chapter 491 has the state Health and Human Services Commission select a consortium to run ibogaine drug development clinical trials, and it bars payment of state funds until matching funds from non-state sources are received and verified. It does not legalize ibogaine. Its treatment provisions apply only if the FDA approves ibogaine to treat a medical condition, and they state that they do not preclude a physician from administering ibogaine in accordance with federal law.

On 31 March 2026 the Lieutenant Governor and the Speaker of the Texas House said the commission had reported that no drug company had submitted a proposal meeting state law and standards, and that Texas would run its own research program. The statement describes $50 million set aside for ibogaine research last session and says the officials intend to fully fund the program. It is a government statement, not a statute, so details of how the program is run may change.

State law varies and changes, and this page does not describe state laws beyond the Texas program above. For any other state, read its current statutes and agency pages.

Mexico: what we can and cannot say

This page does not state whether ibogaine treatment is legal in Mexico. We could not source a Mexican official statement on that question, and a legal conclusion about a clinic or program needs more than we read.

Here is what the one official text we could read does show. The consolidated Ley General de Salud on the Chamber of Deputies site (text current through reforms published in the Diario Oficial on 15 January 2026) classifies psychotropic substances in Article 245. Group I lists substances that include psilocybin, DMT, LSD, MDMA and mescaline. We searched the whole text for ibogaine, iboga and Tabernanthe and found none of those names. Article 244 says psychotropic substances are those named in Article 245 and those that the Consejo de Salubridad General or the Secretaría de Salud specifically determine. Article 246 says the Secretaría determines other substances and publishes the lists in the Diario Oficial.

That absence is not a statement that ibogaine is permitted or prohibited. We did not read those Diario Oficial lists, regulations of the health regulator COFEPRIS, or the rules that govern acts such as supply or prescription. Article 248 prohibits the acts in Article 247 for group I substances, which tells us nothing about a substance the text does not name. A person asking whether a specific activity in Mexico is lawful would need a Mexican lawyer.

Legal status is not a safety signal

A substance's legal position and its medical risk are separate questions. A 2026 review in the journal Addiction describes a rare yet clinically significant cardiotoxic risk, with QTc prolongation and potentially fatal ventricular arrhythmias. Its abstract says case reports show these events occur with therapeutic doses of ibogaine and in individuals without pre-existing cardiac conditions, and that future ibogaine-assisted treatment should be conducted exclusively under controlled medical supervision, with CYP2D6 genotyping and rigorous monitoring of cardiovascular functioning. The abstract does not say that any setting is safe, and neither does this page.

How this page was made

We read each source named here on 30 October 2026, and reopened the federal texts, Texas Chapter 491, the Lieutenant Governor's statement, the Addiction abstract and the FDA announcement again on 31 October 2026 while revising. The federal regulation and Controlled Substances Act sections were read through the Cornell Legal Information Institute mirror, because the official eCFR site blocks automated reading, so confirm them against eCFR and the U.S. Code. The executive order was read in the Federal Register typesetting of the whitehouse.gov PDF. We did not contact any clinic, agency or lawyer. The Spanish-language text is our own reading of the official PDF. Laws and agency actions change, so check current sources before relying on this page. If you or someone you know has a health question about ibogaine or about stopping a substance, talk with a qualified physician.